文献速递白血病造血干细胞移植与细胞治疗

异基因造血干细胞移植治疗23例早期前T细胞急性淋巴细胞白血病的临床研究

[A clinical study of allogeneic hematopoietic stem cell transplantation in 23 patients with early T-cell precursor acute lymphoblastic leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

该研究回顾性分析2010至2018年接受异基因造血干细胞移植的23例ETP-ALL患者,移植前19例达完全缓解、4例未缓解。移植后18个月总生存率为(55.0±14.4)%,无复发生存率为(48.1±14.7)%,移植相关死亡率为4.3%。移植前未缓解者中位OS仅13个月,单倍型与同胞全相合移植疗效相仿。

要点

  • allo-HSCT可改善部分ETP-ALL患者预后,18个月OS率55.0%。
  • 移植前未缓解者中位OS仅13个月,挽救性移植预后不佳。
  • 单倍型与同胞全相合移植的OS及RFS差异无统计学意义。

核心结论

  • 异基因造血干细胞移植可改善部分ETP-ALL患者的预后,但挽救性移植患者预后仍不佳。
  • 单倍型移植与同胞全相合移植治疗ETP-ALL的临床疗效相仿。

研究设计与样本

  • 回顾性分析2010至2018年在苏州大学附属第一医院接受allo-HSCT的23例ETP-ALL患者。
  • ETP-ALL根据流式细胞术免疫表型检测结果诊断,所有患者进行二代测序。
  • 供者类型:12例单倍型移植,7例同胞全相合移植,4例无关供者全相合移植。
  • 移植前19例处于完全缓解状态,4例未缓解。

主要发现

  • 23例患者中男18例、女5例,中位年龄26(12~47)岁。
  • 临床特征:5例初诊WBC>100×10(9)/L,14例脾大,19例外周淋巴结肿大,5例胸腺受累。
  • 11例伴髓系突变,7例具有预后不良核型。
  • 初次诱导化疗后14/23例达CR,5例经多周期化疗后达CR,4例未达CR。
  • 移植后22例完全植入,中性粒细胞和血小板植入中位时间分别为12(9~14)d及19(10~85)d。

关键数值与推荐

  • ETP-ALL诊断依据流式细胞术免疫表型检测结果。
  • 移植前19例达完全缓解,4例未缓解。
  • 18个月OS率为(55.0±14.4)%,RFS率为(48.1±14.7)%。
  • 移植相关死亡率为4.3%。
  • 单倍型与同胞全相合移植OS比较P=0.460,RFS比较P=0.420。

临床怎么用

  • allo-HSCT可作为部分ETP-ALL患者的治疗选择,尤其移植前达CR者。
  • 移植前未缓解者预后差,应重视移植前疾病控制。
  • 单倍型供者可考虑作为ETP-ALL移植的供者来源。

局限性

  • 回顾性研究,样本量仅23例。
  • 中位随访时间11个月,随访期较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a recently recognized high-risk T lymphoblastic leukemia subgroup. The optimal therapeutic approaches to adult patients with ETP-ALL are poorly characterized. In this study, we explore the efficacy and outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for ETP-ALL. Methods: The clinical data of 23 patients with ETP-ALL receiving allo-HSCT from 2010 to 2018 were retrospectively analyzed. Patients with ETP-ALL were diagnosed based on the characteristic immunophenotypes. Second-generation sequencing was done in all patients. As to the donors, 12 patients had haploidentical donors (Haplo-HSCT) , 7 HLA-matched sibling donors (Sib-HSCT) and 4 HLA-matched unrelated donors (URD-HSCT) . Before transplantation, 19 patients achieved complete remission (CR) and 4 patients without. Results: The main clinical features of ETP-ALL included high white blood cell counts in 5 patients, splenomegaly in 14, lymphadenopathy in 19, and thymus masses in 5. According to cytogenetic and molecular characteristics, 11 patients had gene mutations related to myeloid tumors, and 7 with high risk Karyotype. After first induction regimen, 14/23 patients achieved CR. 5 patients reached CR after more than 2 cycles of chemotherapy, while another 4 patients did not reach CR. After allo-HSCT, 22 patients were successfully implanted. The median time of granulocyte and platelet reconstitution was +12 and +19 days. One patient died of transplant-related infection at +14 days. The estimated 18-month overall survival (OS) and relapse-free survival (RFS) rates were (55.0±14.4) % and (48.1±14.7) % respectively. Transplant-related mortality was 4.3%. The median OS in patients achieving CR before transplantation was 20 months, however, that in patients without CR was only 13 months. OS and RFS between haplo-HSCT and sib-HSCT were comparable (P=0.460 and 0.420 respectively) . Conclusions: Allo-HSCT is an effective therapy in some patients with ETP-ALL. Salvage HSCT cannot overcome the poor outcome. Haplo-HSCT and sib-HSCT in ETP-ALL patients have the similar clinical outcome. 目的: 探讨异基因造血干细胞移植(allo-HSCT)治疗急性早前T淋巴细胞白血病(ETP-ALL)的疗效及预后。 方法: 回顾性分析2010-2018年在苏州大学附属第一医院接受allo-HSCT的23例ETP-ALL患者的疗效、相关并发症及预后。ETP-ALL根据流式细胞术免疫表型检测结果诊断。 结果: 23例患者男18例,女5例,中位年龄26(12~47)岁,7例接受同胞全相合移植,4例接受无关供者全相合移植,12例接受单倍型移植,移植前19例患者为完全缓解(CR)状态,4例处于未缓解(NR)状态。ETP-ALL的临床特征:23例患者中,5例初诊时WBC>100×10(9)/L,14例合并脾大,19例合并外周淋巴结肿大,5例合并胸腺受累,11例伴髓系突变,7例具有预后不良核型。所有患者确诊后接受诱导化疗,其中14例在初次化疗后即获得CR,5例经多次化疗后获得CR,4例患者在多次化疗后仍未获得CR。移植结果:22例患者完全植入,其中中性粒细胞和血小板植入中位时间分别为12(9~14)d及19(10~85)d,1例患者于+14 d死于移植相关性感染。中位随访11(1~33)个月,移植后18个月总生存(OS)率为(55.0±14.4)%,无复发生存(RFS)率为(48.1±14.7)%,移植相关死亡率为4.3%。移植前处于CR状态的患者中位OS时间为20个月,NR状态下的患者中位OS时间仅为13个月。19例移植前获得CR的患者中,单倍型移植和同胞全相合移植的OS及RFS差异无统计学意义(P=0.460,P=0.420)。 结论: allo-HSCT可以改善部分ETP-ALL患者的预后,挽救性移植的ETP-ALL患者仍然预后不佳,单倍型移植以及同胞全相合移植治疗ETP-ALL的疗效相仿。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu YX, Zhu MQ, Dai HP, et al. [A clinical study of allogeneic hematopoietic stem cell transplantation in 23 patients with early T-cell precursor acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32023734. doi:10.3760/cma.j.issn.0253-2727.2019.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。